Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
326. |
ECCT/16/11/05 | RV 456: Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo A randomized, obsever-blind, placebo controlled, two-part, Phase 2 study to evaluate the Safety, Tolerability and Immunogenicity of Two prime-boost regimen of the candidate Prophylactic vaccines for Ebola Ad26-ZEBOV and MVA-BN Filo. |
Principal Investigator(s) 1. Fredrick Kipyego Sawe Site(s) in Kenya 1. KEMRI/WRP Kericho (Kericho county) 2. KEMRI/WRP Kombewa, Kisumu (Kisumu county) |
View |
327. |
ECCT/18/07/07 | A Randomized, Open, Parallel-group, Single Dose, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel in combination with Ferroquine (FQ) and FQ alone, in African Patients with Unc A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ alone, in African Patients with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. GRACE KIRINGA KAGUTHI Site(s) in Kenya 1. Center for Respiratory Diseases Research (Siaya county) 2. KEMRI (Kisumu county) |
View |
328. |
ECCT/19/01/01 | A Randomized, Open, Parallel-group, Single Dose, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel in combination with Ferroquine (FQ) and FQ alone, in African Patients with Unc A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ alone, in African Patients with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. Bernhards Ogutu Ragama Site(s) in Kenya 1. Ahero County hospital (Kisumu county) 2. Siaya County Hospital (Siaya county) |
View |
329. |
ECCT/17/05/04 | Ad26.Mos4.HIV Prime/Ad26.Mos4.HIV with Clade C gp140 plus adjuvant +/- Mosaic boost A randomized, parallel-group, placebo-controlled, double-blind Phase 1/2a study in healthy HIV-uninfected adults to assess safety/tolerability and immunogenicity of 2 different prime/boost regimens: priming with tetravalent Ad26.Mos4.HIV and boosting with tetravalent Ad26.Mos4.HIV and either Clade C gp140 plus adjuvant OR a combination of Mosaic and Clade C gp140 plus adjuvant |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya KEMRI WALTER REED KERICHO |
View |
330. |
ECCT/24/08/01 | Evaluate clearance of HPV A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts |
Principal Investigator(s) 1. Fredrick Chite Asirwa 2. Kevin Makori Gesimba Site(s) in Kenya 1. International Cancer Institute (ICI) (Uasin Gishu county) 2. Victoria Cancer Care and Research centre (Nyamira county) |
View |